Frontiers in Psychiatry
January 9, 2024
Terence H W Ching, Lucia Amoroso, Calvin Bohner et al.
9 citations
A randomized controlled trial will test whether two doses of psilocybin (25 mg followed by either 25 or 30 mg), given with non-directive support, reduce obsessive-compulsive disorder (OCD) symptoms more than a single dose or a waitlist control. Thirty adults with treatment-refractory OCD will be enrolled. OCD symptoms will be measured with the Yale-Brown Obsessive-Compulsive Scale – Second Edition by a blinded rater at baseline and after the second dosing week. Participants will be followed for up to 12 months. The trial also aims to identify psychological mechanisms that may explain psilocybin's effects on OCD.
Frontiers in Public Health
December 11, 2024
Amy Bartlett, Challian Christ, Bradford Martins et al.
8 citations
A scoping review of academic literature on the intersection of queer identity and psychedelics found only 18 relevant resources from over 30,000 initially captured, revealing that most existing literature stigmatizes and problematizes queer psychedelic use. The review highlights strong interest among queer populations in using psychedelics for healing and identity development, and emphasizes the need for clinicians to understand queer psychedelic experiences to provide safe, effective care. It recommends future research directions to better explore the meaningful overlap between psychedelics and queerness, aiming to center queer experiences as essential in psychedelic research and practice.
SSRN Electronic Journal
January 1, 2026
Ben Kelemndi, Thomas Adams, Terence H. W. Ching et al.
1 citation
A single dose of psilocybin (0.25 mg/kg) produced rapid, clinically meaningful, and sustained reductions in obsessive-compulsive disorder (OCD) symptoms among adults with treatment-resistant OCD. In a randomized, double-blind, placebo-controlled trial, the psilocybin group showed a 9.76-point decrease on the A-YBOCS at 48 hours, compared to a 0.07-point increase in the niacin group. At one week, 69.2% of psilocybin participants achieved a response (≥35% symptom reduction) versus 0% of niacin participants. Benefits persisted through 12 weeks. One serious adverse event (suicidal ideation) occurred; no treatment-related deaths were reported.
Frontiers in Psychiatry
February 16, 2024
Terence H W Ching, Lucia Amoroso, Calvin Bohner et al.
correction
A correction notice addresses an error in a previously published article on psilocybin therapy for obsessive-compulsive disorder. The notice specifies that the original article's DOI is 10.3389/fpsyt.2023.1278823 and provides the necessary correction. No findings, methods, or results are presented in this text.